β-catenin stabilization enhances SS18-SSX2-driven synovial sarcomagenesis and blocks the mesenchymal to epithelial transition

Oncotarget

Volumn 6, Issue 26, 2015, Pages 22758-22766

  Barrott, Jared J ^a   Illum, Benjamin E ^a   Jin, Huifeng ^a   Zhu, Ju Fen ^a   Mosbruger, Tim ^a   Monument, Michael J ^a   Smith Fry, Kyllie ^a   Cable, Matthew G ^a   Wang, Yanliang ^a   Grossmann, Allie H ^b   Capecchi, Mario R ^c   Jones, Kevin B ^a  

^a UNIVERSITY OF UTAH   (United States)

^b ARUP LABORATORIES   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Epithelial mesenchymal transition; Mouse genetic model; Translocation; Wnt signaling

Indexed keywords

BETA CATENIN; T CELL FACTOR PROTEIN; CTNNB1 PROTEIN, HUMAN; CTNNB1 PROTEIN, MOUSE; ONCOPROTEIN; SYT-SSX FUSION PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL TRANSFORMATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MESENCHYMAL TO EPITHELIAL TRANSITION; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; SYNOVIAL SARCOMA; SYNOVIAL SARCOMA CELL; TRANSCRIPTION REGULATION; TUMOR INVASION; UPREGULATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; TRANSCRIPTION INITIATION; WNT SIGNALING PATHWAY;

ANIMALS; BETA CATENIN; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, FUSION; SARCOMA, SYNOVIAL; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; WNT SIGNALING PATHWAY;

EID: 84941236554     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4283     Document Type: Article

References (20)

1. Herzog CE. Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol. 2005; 27:215-8.
2. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, Brennan MF, Bridge JA, Neff JR, Barr FG, Goldsmith JD, Brooks JS, Goldblum JR, Ali SZ, Shipley J, Cooper CS, Fisher C, Skytting B, Larsson O. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002; 62:135-40.
3. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer cell. 2007; 11:375-88.
4. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004; 5:691-701.
5. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002; 108:837-47.
6. Saito T, Oda Y, Sakamoto A, Kawaguchi K, Tanaka K, Matsuda S, Tamiya S, Iwamoto Y, Tsuneyoshi M. APC mutations in synovial sarcoma. J Pathol. 2002; 196:445-9.
7. Saito T, Oda Y, Sakamoto A, Tamiya S, Kinukawa N, Hayashi K, Iwamoto Y, Tsuneyoshi M. Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma. J Pathol. 2000; 192:342-50.
8. Hasegawa T, Yokoyama R, Matsuno Y, Shimoda T, Hirohashi S. Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma. Hum Pathol. 2001; 32:257-63.
9. Barham W, Frump AL, Sherrill TP, Garcia CB, Saito-Diaz K, Van Saun MN, Fingleton B, Gleaves L, Orton D, Capecchi MR, Blackwell TS, Lee E, Yull F, Eid JE. Targeting the Wnt pathway in synovial sarcoma models. Cancer discovery. 2013; 3:1286-301.
10. Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, Taketo MM. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J. 1999; 18:5931-42.
11. Jagdis A, Rubin BP, Tubbs RR, Pacheco M, Nielsen TO. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Am J Surg Pathol. 2009; 33:1743-51.
12. Haldar M, Hedberg ML, Hockin MF, Capecchi MR. A CreER-based random induction strategy for modeling translocation-associated sarcomas in mice. Cancer research. 2009; 69:3657-64.
13. Straessler KM, Jones KB, Hu H, Jin H, van de Rijn M, Capecchi MR. Modeling clear cell sarcomagenesis in the mouse: cell of origin differentiation state impacts tumor characteristics. Cancer Cell. 2013; 23:215-27.
14. Su L, Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin S, Poulin N, Yi L, Rossi FM, Kast J, Capecchi MR, Underhill TM, Nielsen TO. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer cell. 2012; 21:333-47.
15. Daniels DL, Weis WI. Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nature structural & molecular biology. 2005; 12:364-71.
16. Naka N, Takenaka S, Araki N, Miwa T, Hashimoto N, Yoshioka K, Joyama S, Hamada K, Tsukamoto Y, Tomita Y, Ueda T, Yoshikawa H, Itoh K. Synovial sarcoma is a stem cell malignancy. Stem Cells. 2010; 28:1119-31.
17. Kawai A, Naito N, Yoshida A, Morimoto Y, Ouchida M, Shimizu K, Beppu Y. Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. Cancer Lett. 2004; 204:105-13.
18. Li C, Hung Wong W. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome biology. 2001; 2: RESEARCH0032.
19. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102:15545-50.
20. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome biology. 2014; 15:550.